Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K. DES policy

This article was originally published in The Gray Sheet

Executive Summary

The United Kingdom's National Institute of Health and Clinical Excellence (NICE) completed its final recommendations to the National Health Services of England and Wales on drug-eluting stents and sent advance "confidential" review copies of the policy to stakeholders, including professional societies and stent manufacturers, on Jan. 25, according to an institute spokesperson. The spokesperson would not reveal whether NICE has decided to stick with its August proposal to stop paying for drug-eluting stent procedures in the U.K. or maintain the status quo policy covering the devices in patients with certain disease characteristics. Stakeholders have five days to review the policy in confidence before the agency posts it to its Web site by Feb. 1. The draft released in August concluded drug-eluting stents are not cost-effective compared to bare-metal stents, but groups including the British Cardiovascular Intervention Society and British Cardiac Society have lobbied hard since then to convince the institute otherwise (1"The Gray Sheet" Sept. 3, 2007, p. 3)

You may also be interested in...



Preliminary Recs Would Stop Payments For Drug-Eluting Stents In Britain

A committee meets this week to consider whether to move forward with preliminary recommendations for the Nation Health Service of England and Wales to stop paying for drug-eluting stents

European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway

The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.

Who’s Hired? Apotex Names New US President & CEO

As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles. 

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel